CompoAtlas

Green Up! with GRAMS

Originaltext auf Französisch.

In Kanada zugelassenes natürliches Gesundheitsprodukt

Falls dieses Produkt in Frankreich verkauft würde

Eine Tagesmenge wird nur bei ausdrücklicher oraler Dosierung für Erwachsene berechnet, die pro Tag und in einer zur Produktform passenden festen Einheit angegeben ist. Mehrdeutige Einheiten, Flüssigkeiten, Pulver und pädiatrische Dosen werden nicht hochgerechnet. Eine nicht berechnete Menge wird nicht mit Dosisgrenzwerten verglichen. Diese Analyse stellt weder eine Verkaufszulassung in Frankreich noch eine Sicherheits- oder Wirksamkeitsbewertung dar.

Zusammensetzung

Arzneilicher Inhaltsstoff und QuelleJe Dosiseinheit laut QuelleTäglich höchstens, Erwachsene
Prunus cerasus

Quelle : Prunus cerasus - Fruit

80 mgNicht berechnet
Vaccinium corymbosum

Quelle : Vaccinium corymbosum - Fruit

Extrakt : Matériel brut sec

Extraktionsverhältnis : 8-10:1

Trockenpflanzenäquivalent : 640-800 mg

80 mgNicht berechnet
Petroselinum crispum

Quelle : Petroselinum crispum - herb top

150 mgNicht berechnet
Grifola frondosa

Quelle : Grifola frondosa - Fruiting body

17 mgNicht berechnet
Lycium barbarum

Quelle : Lycium barbarum - Fruit

Extrakt : Matériel brut sec

Extraktionsverhältnis : 12:1

Trockenpflanzenäquivalent : 444 mg

37 mgNicht berechnet
Curcuma longa

Quelle : Curcuma longa - rhizome

17 mgNicht berechnet
Myrciaria dubia

Quelle : Myrciaria dubia - fruit

Extrakt : Matériel brut sec

Extraktionsverhältnis : 18:1

Trockenpflanzenäquivalent : 720 mg

Stärke : 12 % Vitamin C

40 mgNicht berechnet
Malpighia glabra

Quelle : Malpighia glabra - fruit

Extrakt : Matériel brut sec

Extraktionsverhältnis : 10-24:1

Trockenpflanzenäquivalent : 690-1656 mg

Stärke : 17 % Vitamin C

69 mgNicht berechnet
Vaccinium macrocarpon

Extrakt : Matériel brut sec

Extraktionsverhältnis : 9:1

Trockenpflanzenäquivalent : 40 mg

40 mgNicht berechnet
Ganoderma lucidum17 mgNicht berechnet
Lentinula edodes

Quelle : Lentinula edodes - fruiting body

8 mgNicht berechnet
Phyllanthus emblica

Quelle : Phyllanthus emblica - fruit

133 mgNicht berechnet
Euterpe oleracea

Extrakt : Matériel brut sec

Extraktionsverhältnis : 4:1

Trockenpflanzenäquivalent : 436 mg

109 mgNicht berechnet
Camellia sinensis

Quelle : Camellia sinensis - feuille

Extrakt : Matériel brut sec

Extraktionsverhältnis : 5:1

Trockenpflanzenäquivalent : 455 mg

Stärke : 0 3 - 6% Caffeine

91 mgNicht berechnet
Silybum marianum

Quelle : Silybum marianum - Graine

58 mgNicht berechnet
Eleutherococcus senticosus

Quelle : Eleutherococcus senticosus - racine

17 mgNicht berechnet
Rhodiola rosea

Quelle : Rhodiola rosea - Racine

Extrakt : Matériel brut sec

Extraktionsverhältnis : 6:1

Trockenpflanzenäquivalent : 102 mg

Stärke : 1 % Salidroside

17 mgNicht berechnet
Withania somnifera

Quelle : Withania somnifera - racine

Extrakt : Matériel brut sec

Extraktionsverhältnis : 12:1

Trockenpflanzenäquivalent : 204 mg

17 mgNicht berechnet
Astragalus membranaceus

Quelle : Astragalus membranaceus - racine

17 mgNicht berechnet
Schisandra chinensis

Quelle : Schisandra chinensis - fruit

Extrakt : Matériel brut sec

Extraktionsverhältnis : 5:1

Trockenpflanzenäquivalent : 85 mg

17 mgNicht berechnet
Lepidium meyenii

Quelle : Lepidium meyenii - racine

17 mgNicht berechnet
Zingiber officinale

Quelle : Zingiber officinale - Rhizome

17 mgNicht berechnet
Hericium erinaceus17 mgNicht berechnet
Inonotus obliquus

Quelle : Inonotus obliquus - Fruiting body

17 mgNicht berechnet
Camellia sinensis

Quelle : Camellia sinensis - feuille

Stärke : 30 % Catechins

Nicht angegebenNicht berechnet
Medicago sativa

Quelle : Medicago sativa - feuille

233 mgNicht berechnet
Triticum aestivum

Quelle : Triticum aestivum - leaf

233 mgNicht berechnet

Nicht arzneiliche Inhaltsstoffe

Maltodextrine, Lécithine, Isomaltooligosaccharides, Gomme arabique (acacia), Dioxyde de silicium, farine de riz, Huile de tournesol, Solides de sirop de riz

In Kanada empfohlene Dosen

BevölkerungsgruppeAlterMenge pro EinnahmeHäufigkeit
Adultesminimum : 19 ans1 Mesuresminimum : 1 Tous les jours ; maximum : 2 Tous les jours

In Kanada zugelassene Verwendungen

Source of/Provides antioxidants. Source of antioxidants/Provides antioxidants that help fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals. Source of fungal polysaccharides with immunomodulating properties.

Originaltext auf Englisch.

Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.

Warnhinweise in Kanada

Cautions and Warnings : Consult a health care practitioner/health care provider/health care professional/doctor/ physician prior to use if you have a liver disorder or an iron deficiency. Stop use and consult a health care practitioner/health care provider/health care professional/ doctor/physician if you develop symptoms of liver trouble such as yellowing of the skin/eyes (jaundice), stomach pain, dark urine, sweating, nausea, unusual tiredness and/or loss of appetite. Avoid taking with alcohol or products that cause drowsiness. Consult a health care practitioner/health care provider/health care professional/doctor/physician if you have or develop abdominal pain, nausea, fever or vomiting. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you have a history of kidney stones. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you have gallstones, a bile duct obstruction, stomach ulcers or excess stomach acid. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you have any type of acute infection. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you have an autoimmune disorder. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking blood thinners, antidepressant medication, birth control medication or undergoing hormone replacement therapy (HRT).

Originaltext auf Englisch.

Known Adverse Reactions : Rare, unpredictable cases of liver injury associated with green tea extract-containing products have been reported (in Canada and internationally). Stop use if hypersensitivity/allergy occurs. Some people may experience drowsiness. Exercise caution if operating heavy machinery, driving a motor vehicle or involved in activities requiring mental alertness. Stop use if you experience irritability or insomnia. Stop use if laxative effect occurs.

Originaltext auf Englisch.

Contra-Indications : Do not use this product if you are pregnant, breastfeeding or have a history of systemic lupus erythematosus. Do not use this product if you have high blood pressure. Do not use this product if you have bipolar disorder or bipolar spectrum disorder.

Originaltext auf Englisch.

Produktdaten

Andere Namen
Daily G.R.A.M.S., Green Up!, Greens Matrix, Greens powder
Inhaber
CanPrev Natural Health Products Ltd
NPN oder DIN-HM
80124695
Status
Aktive Lizenz
Lizenzdatum
31. Mai 2023
Überarbeitungsdatum
23. Februar 2026
Form
Poudre
Verabreichungsweg
Orale
Art des Antrags
Générale (non traditionelle)

Quelle

Amtlicher Health-Canada-Eintrag, Zulassung 80124695

Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Originaltext auf Englisch.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Originaltext auf Französisch.

Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.

Offizielle Warnhinweise (Health Canada)

Health Canada veröffentlicht Warnhinweise zu diesen Zutaten:

  • Vaccinium corymbosum
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    Blueberry

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Gilt für Produkte: providing 5 grams or more of total dried fruit, per day; Products providing 37.5 grams or more of total fresh fruit, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (ASHP 2005; Franco et al. 2004; IOM 2001; Hansten et al. 1997).

    Von Health Canada zitierte Quellen (4)
    • ASHP 2005: American Society of Health-System Pharmacists. American Hospital Formulary Service (AHFS) Drug Information. Philadelphia (PA): Lippincott Williams and Wilkins; 2005.
    • Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. The American Journal of Medicine 2004;166(10):651-656. PubMed Randomisierte Studie
    • Hansten PD, Horn JR, editors. Drug Interactions Analysis and Management. Vancouver (WA): Applied Therapeutics Inc.; 1997.
    • IOM 2001: Institute of Medicine. Panel on Micronutrients, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington (DC): National Academies Press; 2001.

    Monografie von Health Canada vom 29. August 2025

  • Curcuma longa
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    TURMERIC - CURCUMA LONGA - Oral

    Art der Anwendung: Oral (ESCOP 2003; Blumenthal et al. 2000)

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (ESCOP 2003; Brinker 2001; McGuffin et al. 1997).

    Von Health Canada zitierte Quellen (2)
    • ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder (HC 2025; EMA 2018; Brinker 2010; ESCOP 2003; McGuffin et al. 1997).

    Von Health Canada zitierte Quellen (6)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2018. European Medicines Agency. European Union herbal monograph on Curcuma longa L., rhizome. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 25 September 2018. [Accessed 2023 October 14] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf
    • ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).

    Von Health Canada zitierte Quellen (2)
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).

    Von Health Canada zitierte Quellen (2)
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Anwendungsbedingung: All uses except for Source of antioxidants and Hepatoprotectant.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografie von Health Canada vom 26. September 2025

    Turmeric -CURCUMA LONGA - Topical

    Vorsichtsmaßnahmen und Warnhinweise

    For external use only.

    When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.

    Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.

    Gegenanzeigen

    Do not use on deep or puncture wounds, animal bites or serious burns.

    Monografie von Health Canada vom 28. Februar 2025

  • Vaccinium macrocarpon
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    CRANBERRY - VACCINIUM MACROCARPON

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Von Health Canada zitierte Quellen (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomisierte Studie
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Von Health Canada zitierte Quellen (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Fallbericht
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Anwendungsbedingung: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografie von Health Canada vom 27. März 2026

    DRIED CRANBERRY JUICE

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Von Health Canada zitierte Quellen (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomisierte Studie
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Von Health Canada zitierte Quellen (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Fallbericht
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Anwendungsbedingung: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografie von Health Canada vom 27. März 2026

  • Phyllanthus emblica
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    Amla - Phyllanthus Emblica

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (HC 2009).

    Von Health Canada zitierte Quellen (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Gilt für Produkte: providing more than 3 grams of amla, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (HC 2009).

    Von Health Canada zitierte Quellen (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Anwendungsbedingung: Amlapitta, Digestive tonic.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Anwendungsbedingung: Laxative.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (HC 2009; Pray 2006; CPhA 2002).

    Von Health Canada zitierte Quellen (3)
    • CPhA 2002: Repchinsky C, editor-in-chief. Patient Self-Care: Helping Patients Make Therapeutic Choices. 1st edition. Ottawa (ON): Canadian Pharmacists Association; 2002.
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
    • Pray WS. Non-Prescription Product Therapeutics. 2nd edition. New York (NY): Lippincott Williams & Wilkins; 2006.

    Gegenanzeigen

    Anwendungsbedingung: Laxative.

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).

    Von Health Canada zitierte Quellen (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Bekannte Nebenwirkungen

    Anwendungsbedingung: Amlapitta, Antioxidant, Digestive tonic, Rasayana or Eye tonic.

    When using this product you may experience a laxative effect.

    Monografie von Health Canada vom 28. März 2025

  • Euterpe oleracea
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    ACAI – EUTERPE OLERACEA

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (derMarderosian and Beutler 2008).

    Von Health Canada zitierte Quellen (1)
    • derMarderosian A, Beutler JA, editors. The Review of Natural Products. [Acai: Date of issue January 2008]. St Louis (MO): Facts and Comparisons, Wolters Kluwer Health; Printed in 2008 and Updated to April 2012.

    Bekannte Nebenwirkungen

    Stop use if hypersensitivity/allergy occurs (derMarderosian and Beutler 2008).

    Von Health Canada zitierte Quellen (1)
    • derMarderosian A, Beutler JA, editors. The Review of Natural Products. [Acai: Date of issue January 2008]. St Louis (MO): Facts and Comparisons, Wolters Kluwer Health; Printed in 2008 and Updated to April 2012.

    Monografie von Health Canada vom 24. April 2026

  • Silybum marianum
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    MILK THISTLE - SILYBUM MARIANUM

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills et al. 2006).

    Von Health Canada zitierte Quellen (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills E, Dugoua J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (UK): Taylor and Francis Medical; 2006.

    Bekannte Nebenwirkungen

    Stop use if hypersensitivity/allergy occurs (Geier et al. 1990; Mironets et al. 1990).

    Von Health Canada zitierte Quellen (2)
    • Geier J, Fuchs Th, Wahl R. [Anaphylactic shock due to an extract of Silybum marianum in a patient with immediate-type allergy to Kiwi fruit]. Anaphylaktischer Schock durch einen Mariendistel-Extrakt bei Soforttyp-Allergie auf Kiwi. Allergologie 1990;13(10):387-388 (in German).
    • Mironets VI, Krasovskaia EA, Polischuk II. [A case of urticaria during carsil treatment]. Vrachebnoe Delo 1990;(7):86-87 (in Russian).

    Monografie von Health Canada vom 26. Juni 2026

  • Eleutherococcus senticosus
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    ELEUTHERO - ELEUTHEROCOCCUS SENTICOSUS

    Art der Anwendung: Oral (ESCOP 2003; Bradley 1992)

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).

    Von Health Canada zitierte Quellen (2)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an acute infection (Brinker 2010; Mills and Bone 2000).

    Von Health Canada zitierte Quellen (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.

    Gegenanzeigen

    Do not use if you have high blood pressure (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000; Mills and Bone 2000).

    Von Health Canada zitierte Quellen (5)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.

    Monografie von Health Canada vom 31. Oktober 2025

  • Withania somnifera
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    ASHWAGANDHA - WITHANIA SOMNIFERA

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).

    Von Health Canada zitierte Quellen (3)
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
    • Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).

    Von Health Canada zitierte Quellen (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
    • Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.

    Monografie von Health Canada vom 28. Februar 2025

  • Astragalus membranaceus
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    ASTRAGALUS - ASTRAGALUS MEMBRANACEUS

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an autoimmune disorder (Brinker 2010; Upton 1999).

    Von Health Canada zitierte Quellen (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Astragalus Root. Santa Cruz (CA): American Herbal Pharmacopoeia; 1999.

    Gegenanzeigen

    Anwendungsbedingung: Traditional Chinese Medicine.

    Do not use if you have exterior excess, stagnation, yin deficiency or excess heat (Bensky et al. 2004; Chen and Chen 2004).

    Von Health Canada zitierte Quellen (2)
    • Bensky D, Clavey, Stöger E, Gamble A. Chinese Herbal Medicine: Materia Medica. 3rd edition. Seattle (WA): Eastland Press, Incorporated; 2004.
    • Chen JK, Chen TT. Chinese Medical Herbology and Pharmacology. Crampton L, editor. City of Industry (CA): Art of Medicine Press Inc.; 2004.

    Monografie von Health Canada vom 30. Mai 2025

  • Lepidium meyenii
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    Maca - Lepidium Meyenii

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Gilt für Produkte: providing 0.6 g or more dried root/hypocotyl, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a blood pressure condition (Valentova et al. 2008).

    Von Health Canada zitierte Quellen (1)
    • Valentova K, Stejskal D, Bartek J, Dvoráckova S, Kren V, Ulrichova J, Simanek V. Maca (Lepidium meyenii) and yacon (Smallanthus sonchifolius) in combination with silymarin as food supplements: in vivo safety assessment. Food and Chemical Toxicology 2008;46(3):1006-1013. PubMed Randomisierte Studie

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Gonzales and Gonzales-Castaneda 2009; Dording et al. 2008).

    Von Health Canada zitierte Quellen (2)
    • Dording CM, Fsher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapy and Therapeutics 2008;14(3):182-191. PubMed Randomisierte Studie
    • Gonzales GF, Gonzales-Castaneda GC. The Methyltetrahydro-{beta}-Carbolines in Maca (Lepidium meyenii). Evidence Based Complementary Alternative Medicine 2009;6(3):315-316. PubMed

    Anwendungsbedingung: Healthy mood balance; Sexual health.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have psychological disorders such as anxiety or depression (Brotto 2010; Gonzales and Gonzales-Castaneda 2009; Dording et al. 2008).

    Von Health Canada zitierte Quellen (3)
    • Brotto LA. The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Archives of Sexual Behavior 2010;39(2):221-239. PubMed Übersichtsartikel
    • Dording CM, Fsher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapy and Therapeutics 2008;14(3):182-191. PubMed Randomisierte Studie
    • Gonzales GF, Gonzales-Castaneda GC. The Methyltetrahydro-{beta}-Carbolines in Maca (Lepidium meyenii). Evidence Based Complementary Alternative Medicine 2009;6(3):315-316. PubMed

    Monografie von Health Canada vom 27. September 2024

  • Zingiber officinale
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    GINGER - ZINGIBER OFFICINALE

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografie von Health Canada vom 19. Dezember 2025

  • Medicago sativa
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    ALFALFA - MEDICAGO SATIVA

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Gilt für Produkte: providing more than 900 mg of Alfalfa dried herb top/leaf, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners, birth control medication or hormone therapy (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).

    Von Health Canada zitierte Quellen (3)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): Pharmaceutical Press; 2007.
    • Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
    • Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.

    Gegenanzeigen

    Anwendungsbedingung: All products.

    Do not use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).

    Von Health Canada zitierte Quellen (3)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): Pharmaceutical Press; 2007.
    • Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
    • Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.

    Gilt für Produkte: providing more than 900 mg of Alfalfa dried herb top/leaf, per day.

    Do not use if you have a history of systemic lupus erythematosus (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).

    Von Health Canada zitierte Quellen (3)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): Pharmaceutical Press; 2007.
    • Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
    • Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.

    Monografie von Health Canada vom 29. November 2024

Sie betreffen die Zutat, nicht dieses Produkt oder seine Dosis. Sie ersetzen keinen ärztlichen Rat.

Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).

Das Produkt hat sich geändert? Fotografieren Sie die Verpackung.

Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.

Eingabetaste zum Analysieren, Umschalt+Eingabetaste für eine neue Zeile